CD8A and neoplasm: Globally, the results obtained demonstrate that the boosted PBMC-hu-NSG-A2 mouse model is suitable to target Clec9A DCs, which are emerging as major players in the onset of anti-tumor responses [51], and to investigate the extent and quality of CD4+ and CD8+ T cell responses specific for a variety of different tumor epitopes.